Use of antiparkinsonian drugs in Denmark : Results from a nationwide pharmacoepidemiological study
Identifieur interne : 001852 ( PascalFrancis/Checkpoint ); précédent : 001851; suivant : 001853Use of antiparkinsonian drugs in Denmark : Results from a nationwide pharmacoepidemiological study
Auteurs : Mette Brandt-Christensen [Danemark] ; Kajsa Kvist [Danemark] ; Flemming M Rkeberg Nilsson [Danemark] ; Per Kragh Andersen [Danemark] ; Lars Vedel Kessing [Danemark]Source :
- Movement disorders [ 0885-3185 ] ; 2006.
Descripteurs français
- Pascal (Inist)
- Wicri :
- geographic : Danemark.
- topic : Base de données.
English descriptors
Abstract
The objective of the present study was to record the use of antiparkinsonian drugs (APD) in Denmark and discuss estimates of the incidence and prevalence rates of Parkinson's disease (PD). The main indication for treatment with APD is idiopathic PD. The use of APD is, therefore, an indicator of the epidemiology of PD and Parkinsonism. We used a drug tracer design, which previously has been found applicable in estimating the frequency of PD. From a national prescription database, all persons who purchased APD from 1995 to 2002 could be identified on an individual level. Results show an age-standardized prevalence rate for APD purchase of 164.0 persons per 100,000, and an incidence rate of 55.9 persons per 100,000. The total number of persons purchasing APD was 11,656 per year on average. Our results showed higher figures of persons purchasing APD than the estimated prevalence of idiopathic PD in Denmark, which is approximately 100 persons per 100,000, corresponding to 5,000 to 6,000 persons. The differences might in part be explained by other indications for APD prescription in addition to PD and in part by misdiagnosis. However, the possibility of somewhat higher incidence and prevalence rates of PD than hitherto estimated should be considered.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:06-0435097Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Use of antiparkinsonian drugs in Denmark : Results from a nationwide pharmacoepidemiological study</title><author><name sortKey="Brandt Christensen, Mette" sort="Brandt Christensen, Mette" uniqKey="Brandt Christensen M" first="Mette" last="Brandt-Christensen">Mette Brandt-Christensen</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Psychiatry, University Hospital of Copenhagen Rigshospitalet</s1><s3>DNK</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Danemark</country><wicri:noRegion>Department of Psychiatry, University Hospital of Copenhagen Rigshospitalet</wicri:noRegion></affiliation></author><author><name sortKey="Kvist, Kajsa" sort="Kvist, Kajsa" uniqKey="Kvist K" first="Kajsa" last="Kvist">Kajsa Kvist</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Biosfatistics, University of Copenhagen</s1><s2>Copenhagen</s2><s3>DNK</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Danemark</country><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Nilsson, Flemming M Rkeberg" sort="Nilsson, Flemming M Rkeberg" uniqKey="Nilsson F" first="Flemming M Rkeberg" last="Nilsson">Flemming M Rkeberg Nilsson</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Psychiatry, Amager Hospital</s1><s2>Copenhagen</s2><s3>DNK</s3><sZ>3 aut.</sZ></inist:fA14><country>Danemark</country><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Andersen, Per Kragh" sort="Andersen, Per Kragh" uniqKey="Andersen P" first="Per Kragh" last="Andersen">Per Kragh Andersen</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Biosfatistics, University of Copenhagen</s1><s2>Copenhagen</s2><s3>DNK</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Danemark</country><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Kessing, Lars Vedel" sort="Kessing, Lars Vedel" uniqKey="Kessing L" first="Lars Vedel" last="Kessing">Lars Vedel Kessing</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Psychiatry, University Hospital of Copenhagen Rigshospitalet</s1><s3>DNK</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Danemark</country><wicri:noRegion>Department of Psychiatry, University Hospital of Copenhagen Rigshospitalet</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">06-0435097</idno><date when="2006">2006</date><idno type="stanalyst">PASCAL 06-0435097 INIST</idno><idno type="RBID">Pascal:06-0435097</idno><idno type="wicri:Area/PascalFrancis/Corpus">001A41</idno><idno type="wicri:Area/PascalFrancis/Curation">001280</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001852</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Use of antiparkinsonian drugs in Denmark : Results from a nationwide pharmacoepidemiological study</title><author><name sortKey="Brandt Christensen, Mette" sort="Brandt Christensen, Mette" uniqKey="Brandt Christensen M" first="Mette" last="Brandt-Christensen">Mette Brandt-Christensen</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Psychiatry, University Hospital of Copenhagen Rigshospitalet</s1><s3>DNK</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Danemark</country><wicri:noRegion>Department of Psychiatry, University Hospital of Copenhagen Rigshospitalet</wicri:noRegion></affiliation></author><author><name sortKey="Kvist, Kajsa" sort="Kvist, Kajsa" uniqKey="Kvist K" first="Kajsa" last="Kvist">Kajsa Kvist</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Biosfatistics, University of Copenhagen</s1><s2>Copenhagen</s2><s3>DNK</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Danemark</country><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Nilsson, Flemming M Rkeberg" sort="Nilsson, Flemming M Rkeberg" uniqKey="Nilsson F" first="Flemming M Rkeberg" last="Nilsson">Flemming M Rkeberg Nilsson</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Psychiatry, Amager Hospital</s1><s2>Copenhagen</s2><s3>DNK</s3><sZ>3 aut.</sZ></inist:fA14><country>Danemark</country><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Andersen, Per Kragh" sort="Andersen, Per Kragh" uniqKey="Andersen P" first="Per Kragh" last="Andersen">Per Kragh Andersen</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Biosfatistics, University of Copenhagen</s1><s2>Copenhagen</s2><s3>DNK</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Danemark</country><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Kessing, Lars Vedel" sort="Kessing, Lars Vedel" uniqKey="Kessing L" first="Lars Vedel" last="Kessing">Lars Vedel Kessing</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Psychiatry, University Hospital of Copenhagen Rigshospitalet</s1><s3>DNK</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Danemark</country><wicri:noRegion>Department of Psychiatry, University Hospital of Copenhagen Rigshospitalet</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2006">2006</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Database</term><term>Denmark</term><term>Epidemiology</term><term>Levodopa</term><term>Nervous system diseases</term><term>Parkinson disease</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term><term>Parkinson maladie</term><term>Danemark</term><term>Epidémiologie</term><term>Lévodopa</term><term>Base donnée</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Danemark</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Base de données</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of the present study was to record the use of antiparkinsonian drugs (APD) in Denmark and discuss estimates of the incidence and prevalence rates of Parkinson's disease (PD). The main indication for treatment with APD is idiopathic PD. The use of APD is, therefore, an indicator of the epidemiology of PD and Parkinsonism. We used a drug tracer design, which previously has been found applicable in estimating the frequency of PD. From a national prescription database, all persons who purchased APD from 1995 to 2002 could be identified on an individual level. Results show an age-standardized prevalence rate for APD purchase of 164.0 persons per 100,000, and an incidence rate of 55.9 persons per 100,000. The total number of persons purchasing APD was 11,656 per year on average. Our results showed higher figures of persons purchasing APD than the estimated prevalence of idiopathic PD in Denmark, which is approximately 100 persons per 100,000, corresponding to 5,000 to 6,000 persons. The differences might in part be explained by other indications for APD prescription in addition to PD and in part by misdiagnosis. However, the possibility of somewhat higher incidence and prevalence rates of PD than hitherto estimated should be considered.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>21</s2></fA05><fA06><s2>8</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Use of antiparkinsonian drugs in Denmark : Results from a nationwide pharmacoepidemiological study</s1></fA08><fA11 i1="01" i2="1"><s1>BRANDT-CHRISTENSEN (Mette)</s1></fA11><fA11 i1="02" i2="1"><s1>KVIST (Kajsa)</s1></fA11><fA11 i1="03" i2="1"><s1>NILSSON (Flemming Mørkeberg)</s1></fA11><fA11 i1="04" i2="1"><s1>ANDERSEN (Per Kragh)</s1></fA11><fA11 i1="05" i2="1"><s1>KESSING (Lars Vedel)</s1></fA11><fA14 i1="01"><s1>Department of Psychiatry, University Hospital of Copenhagen Rigshospitalet</s1><s3>DNK</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></fA14><fA14 i1="02"><s1>Department of Biosfatistics, University of Copenhagen</s1><s2>Copenhagen</s2><s3>DNK</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ></fA14><fA14 i1="03"><s1>Department of Psychiatry, Amager Hospital</s1><s2>Copenhagen</s2><s3>DNK</s3><sZ>3 aut.</sZ></fA14><fA20><s1>1221-1225</s1></fA20><fA21><s1>2006</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000142193570280</s5></fA43><fA44><s0>0000</s0><s1>© 2006 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>27 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>06-0435097</s0></fA47><fA60><s1>P</s1><s3>CC</s3></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>The objective of the present study was to record the use of antiparkinsonian drugs (APD) in Denmark and discuss estimates of the incidence and prevalence rates of Parkinson's disease (PD). The main indication for treatment with APD is idiopathic PD. The use of APD is, therefore, an indicator of the epidemiology of PD and Parkinsonism. We used a drug tracer design, which previously has been found applicable in estimating the frequency of PD. From a national prescription database, all persons who purchased APD from 1995 to 2002 could be identified on an individual level. Results show an age-standardized prevalence rate for APD purchase of 164.0 persons per 100,000, and an incidence rate of 55.9 persons per 100,000. The total number of persons purchasing APD was 11,656 per year on average. Our results showed higher figures of persons purchasing APD than the estimated prevalence of idiopathic PD in Denmark, which is approximately 100 persons per 100,000, corresponding to 5,000 to 6,000 persons. The differences might in part be explained by other indications for APD prescription in addition to PD and in part by misdiagnosis. However, the possibility of somewhat higher incidence and prevalence rates of PD than hitherto estimated should be considered.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B02B06</s0></fC02><fC02 i1="03" i2="X"><s0>002B02U10</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Danemark</s0><s2>NG</s2><s5>09</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Denmark</s0><s2>NG</s2><s5>09</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Dinamarca</s0><s2>NG</s2><s5>09</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Epidémiologie</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Epidemiology</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Epidemiología</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Lévodopa</s0><s2>NK</s2><s2>FR</s2><s5>11</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Levodopa</s0><s2>NK</s2><s2>FR</s2><s5>11</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Levodopa</s0><s2>NK</s2><s2>FR</s2><s5>11</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Base donnée</s0><s5>12</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Database</s0><s5>12</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Base dato</s0><s5>12</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Europe</s0><s2>NG</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Europe</s0><s2>NG</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Europa</s0><s2>NG</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Encéphale pathologie</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>37</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>38</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>39</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>40</s5></fC07><fN21><s1>289</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Danemark</li></country><region><li>Hovedstaden</li></region><settlement><li>Copenhague</li></settlement></list><tree><country name="Danemark"><noRegion><name sortKey="Brandt Christensen, Mette" sort="Brandt Christensen, Mette" uniqKey="Brandt Christensen M" first="Mette" last="Brandt-Christensen">Mette Brandt-Christensen</name></noRegion><name sortKey="Andersen, Per Kragh" sort="Andersen, Per Kragh" uniqKey="Andersen P" first="Per Kragh" last="Andersen">Per Kragh Andersen</name><name sortKey="Kessing, Lars Vedel" sort="Kessing, Lars Vedel" uniqKey="Kessing L" first="Lars Vedel" last="Kessing">Lars Vedel Kessing</name><name sortKey="Kvist, Kajsa" sort="Kvist, Kajsa" uniqKey="Kvist K" first="Kajsa" last="Kvist">Kajsa Kvist</name><name sortKey="Nilsson, Flemming M Rkeberg" sort="Nilsson, Flemming M Rkeberg" uniqKey="Nilsson F" first="Flemming M Rkeberg" last="Nilsson">Flemming M Rkeberg Nilsson</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001852 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 001852 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:06-0435097
|texte= Use of antiparkinsonian drugs in Denmark : Results from a nationwide pharmacoepidemiological study
}}
| This area was generated with Dilib version V0.6.23. |  |